Refine by
Cancerous Target Suppliers & Manufacturers
37 companies found
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a ...
based inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
Rigosertib is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth while having little effect on normal cells. In contrast to many kinase inhibitors, rigosertib does not interact at the ATP binding site, but ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inCleveland, OHIO (USA)
Advances in cancer diagnostics have enabled the detection of cancer at its earliest stages when the chances for successful intervention are highest. For many tumors, surgery offers the best option for a cure, with the potential to remove all cancer ...
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over ...
based inBentley, AUSTRALIA
Based in Perth, Western Australia, Epichem was established in 2003 and was driven by a desire to solve difficult synthetic chemistry problems and to provide jobs for home grown PhD organic chemists. We are Australia’s leading provider of synthetic ...
based inKerrville, TEXAS (USA)
Vitanova Biomedical, Inc. (VNB) is a San Antonio, TX-based early stage biotechnology company developing patented (pending) technology licensed from the University of Texas at San Antonio. The company’s cancer treatment, Light-Activated Intracellular ...
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit ...
based inSeville, SPAIN
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
Glycosylation is a post-translational modification that occurs inside the cell and results in the addition of sugar motifs, “glycans”, to proteins and lipids that are, in most cases, destined for the cell surface. These glycan structures ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These ...
based inAustin, TEXAS (USA)
Breath science is rapidly growing — and we are growing with it Advances in analytical chemistry have accelerated the pace of exhaled biomarker research. New breath diagnostics targeting cancer, asthma, infections, and other conditions are rapidly ...
based inSchlieren, SWITZERLAND
Elthera AG is a Swiss biopharmaceutical company founded in 2016 by experienced Pharma and Biotech executives with the goal of developing proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing ...
based inTucson, ARIZONA (USA)
Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better ...
Only 4 of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009, but this medicine did not extend life expectancy. Patients deserve better therapies that extend life and ...
based inWaterside, UNITED KINGDOM
Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by ...
An advanced guidance system designed for intracavity radio-guided surgery. The miniaturized SENSEI® probe enables unprecendented dexterity and anatomic reach, expanding the field of view and enabling the quick localization of radioactive ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
A key step in drug discovery is target identification—identifying "druggable" biological targets. After a target is identified, it must be validated to demonstrate the functional relationship between the target and disease phenotype while ensuring ...
based inMarcy l`Etoile, FRANCE
Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. A family-owned company, bioMérieux has grown to become a world leader in the ...
based inPrinceton, NEW JERSEY (USA)
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...